GLOW Dosage: Doses Studied, Units and Chart
What doses of GLOW have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 27 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- less than 30 min
- IV and IM (single and repeated), rat, beagle dog · Frontiers in pharmacology 2022, PMID 36588717
- Vial sizes sold
- 50 mg, 70 mg
Doses used in published studies
No study has tested GLOW itself. These are the doses used in studies of each ingredient, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| TB-500: 0.05 to 25.0 ug/kg single; 0.5, 2.0 and 5.0 ug/kg daily | single dose or once daily · intravenous · 10 days (multiple-dose cohorts) | Human RCT | Journal of cellular and molecular medicine 2021, PMID 34346165 |
| TB-500: 0.5 mg/ml gel | topical (scalp) · 4 weeks | Human controlled trialn = 71 | Microbial biotechnology 2021, PMID 34318587 |
| TB-500: 0.1% | 6 times daily · eye drops · 28 days | Human RCTn = 9 | Cornea 2015, PMID 25826322 |
| TB-500: 0.1% | eye drops · 28 days | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: 42, 140, 420 or 1260 (mg, as stated in abstract) | single dose, then daily · intravenous · 14 days | Human RCTn = 40 | Annals of the New York Academy of Sciences 2010, PMID 20536472 |
| TB-500: topical, 0.03% dose highlighted | topical | Human RCTn = 73 | Annals of the New York Academy of Sciences 2010, PMID 20536470 |
| BPC-157: 10 mg (day 1) and 20 mg (day 2) in 250 cc normal saline | once daily on 2 consecutive days · intravenous infusion over one hour · 2 days | Human uncontrolled trialn = 2 | Alternative therapies in health and medicine 2025, PMID 40131143 |
| BPC-157: 10 mg total | single procedure · injection around the inflamed bladder area during cystoscopy | Human uncontrolled trialn = 12 | Alternative therapies in health and medicine 2024, PMID 39325560 |
| BPC-157: BPC-157 10 ug/kg/day; TB-500 60 ug/kg/day | daily · intraperitoneal · four weeks | Animal · rat (not a human result)n = 32 | Joint diseases and related surgery 2026, PMID 42542926 |
| TB-500: TB-500 60 ug/kg/day; BPC-157 10 ug/kg/day | daily · intraperitoneal · four weeks | Animal · rat (not a human result)n = 32 | Joint diseases and related surgery 2026, PMID 42542926 |
| BPC-157: 10, 20 or 40 ug/kg | Not stated in the abstract | Animal · rat (not a human result) | Journal of dental anesthesia and pain medicine 2022, PMID 35449779 |
| BPC-157: 10 ng/kg, 10 ug/kg | intraperitoneal | Animal · rat (not a human result) | Biomedicines 2022, PMID 35203478 |
| BPC-157: 0.4 ug/eye, 0.4 ng/eye; 10 ug/kg, 10 ng/kg | eye drops, intraperitoneal or drinking water · six weeks | Animal · rat (not a human result) | Biomedicines 2021, PMID 35052769 |
| BPC-157: 200 or 2 ug/kg | single injection 10 min after injury · intraperitoneal | Animal · rat (not a human result) | Journal of orthopaedic surgery and research 2019, PMID 31266512 |
| BPC-157: 10 ug/kg | bath applied to the colon segment | Animal · rat (not a human result) | World journal of gastroenterology 2017, PMID 29358856 |
| GHK-Cu: 0.3 or 3 mg/ml | once a week · intra-articular injection · 4 weeks | Animal · rat (not a human result)n = 72 | Journal of orthopaedic research 2015, PMID 25731775 |
| TB-500: 2, 12 or 18 mg/kg | 24 h after stroke then every 3 days for 4 additional doses · intraperitoneal | Animal · rat (not a human result)n = 10 | Journal of the neurological sciences 2014, PMID 25060418 |
| BPC-157: 10 ug/kg or 10 ng/kg | once daily · intraperitoneal or in drinking water | Animal · rat (not a human result) | Journal of physiology and pharmacology 2013, PMID 24304574 |
| TB-500: 1 ug in 100 uL fibrin sealant | single placement at surgery · local, in the ligament gap | Animal · rat (not a human result) | Regulatory peptides 2013, PMID 23523891 |
| TB-500: 10 mg N-acetylated LKKTETQ | single dose | Animal · horse (not a human result) | Journal of chromatography. A 2012, PMID 23084823 |
| BPC-157: 10 microg or 10 ng/kg i.p.; 1.0 microg/g cream topically; 0.16 microg/ml in drinking water | once daily · intraperitoneal, topical cream or oral (drinking water) | Animal · rat (not a human result) | Journal of orthopaedic research 2010, PMID 20225319 |
| BPC-157: 10 microg, 10 ng/kg | intraperitoneal, intragastric or local | Animal · rat (not a human result) | Regulatory peptides 2010, PMID 19903499 |
| BPC-157: 10 microg/kg, 10 ng/kg | continuously in drinking water, or once daily i.p. · drinking water or intraperitoneal | Animal · rat (not a human result) | Journal of pharmacological sciences 2008, PMID 18818478 |
| BPC-157: 1 microg, 1 ng or 1 pg per g of neutral cream | once daily · topical cream | Animal · mouse (not a human result) | Burns 2005, PMID 15774286 |
| BPC-157: 10 microg, 10 ng or 10 pg/kg | once daily, first dose 30 min after surgery · intraperitoneal | Animal · rat (not a human result) | Journal of orthopaedic research 2003, PMID 14554208 |
| BPC-157: 10 microg or 10 ng/kg | once daily (postoperative days 7-21) or intermittent doses on postoperative days 7, 9, 14 and 16 · local percutaneous or intramuscular · postoperative days 7-21 for the daily regimen | Animal · rabbit (not a human result) | Bone 1999, PMID 10071911 |
| TB-500: 400 micrograms | intraperitoneal | Animal · mouse (not a human result) | International journal of immunopharmacology 1997, PMID 9226473 |
Dose to syringe units
For a 50 mg vial mixed with 2 mL of bacteriostatic water (25 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 0.25 mg
- 1 u
- 0.5 mg
- 2 u
- 1 mg
- 4 u
- 2 mg
- 8 u
- 2.5 mg
- 10 u
- 5 mg
- 20 u
Before anyone considers it
- GLOW is Not FDA approved · unstudied blend; research-chemical versions are not the approved drug.
- Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
How many units is 1 mg of GLOW?
It depends on the water added. A 50 mg vial with 2 mL of water gives 25 mg/mL, so 1 mg is 4 units on a U-100 syringe. Use the calculator for other mixes.
Is GLOW FDA approved?
GLOW is Not FDA approved · unstudied blend. Products sold as research chemicals are not the approved drug and are not checked by the FDA.
More on GLOW
Side effectsWhat labels and studies report, and what is unknown.Blend calculatorSplit a blend vial into per-peptide amounts and units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How to injectSites, syringe types and hygiene, step by step.StoragePowder and mixed vials: temperature and shelf life.
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
- 4Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 5Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 6Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 7A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.Annals of the New York Academy of Sciences · 2010PMID 20536472Accessed 2 Oct 2026
- 8The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
- 9Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 10Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 11Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 12The anti-nociceptive effect of BPC-157 on the incisional pain model in rats.Journal of dental anesthesia and pain medicine · 2022PMID 35449779Accessed 2 Oct 2026
- 13Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.Biomedicines · 2022PMID 35203478Accessed 2 Oct 2026
- 14Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.Biomedicines · 2021PMID 35052769Accessed 2 Oct 2026
- 15Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.Journal of orthopaedic surgery and research · 2019PMID 31266512Accessed 2 Oct 2026
- 16Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights.World journal of gastroenterology · 2017PMID 29358856Accessed 2 Oct 2026
- 17Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
- 18A dose-response study of thymosin β4 for the treatment of acute stroke.Journal of the neurological sciences · 2014PMID 25060418Accessed 2 Oct 2026
- 19Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2013PMID 24304574Accessed 2 Oct 2026
- 20Thymosin β4 enhances the healing of medial collateral ligament injury in rat.Regulatory peptides · 2013PMID 23523891Accessed 2 Oct 2026
- 21Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 22Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2010PMID 20225319Accessed 2 Oct 2026
- 23Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.Regulatory peptides · 2010PMID 19903499Accessed 2 Oct 2026
- 24Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.Journal of pharmacological sciences · 2008PMID 18818478Accessed 2 Oct 2026
- 25The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice.Burns : journal of the International Society for Burn Injuries · 2005PMID 15774286Accessed 2 Oct 2026
- 26Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003PMID 14554208Accessed 2 Oct 2026
- 27Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation.Bone · 1999PMID 10071911Accessed 2 Oct 2026
- 28Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice.International journal of immunopharmacology · 1997PMID 9226473Accessed 2 Oct 2026
- 29Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
Found an error? Report a correction.